Promoted Content Promoted Content

X

Find Ophthalmology Drugs in Phase II Clinical Development in SWITZERLAND

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Dexamethasone

            Therapeutic Area: Ophthalmology Product Name: OCS-01

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: BVCF Management

            Deal Size: $57.0 million Upfront Cash: Undisclosed

            Deal Type: Series C Financing May 04, 2021

            Details:

            Proceeds from this financing will accelerate OCS-01 into Phase 3 trials in Diabetic Macular Edema (DME) and complete registration studies in the treatment of Inflammation and Pain following Ocular Surgery, and other pipeline activities.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Dexamethasone

            Therapeutic Area: Ophthalmology Product Name: OCS-01

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 05, 2020

            Details:

            The Phase 2 trial met its pre-specified efficacy endpoints and showed that OCS-01 eye drops were more effective than vehicle in reducing central macular thickness and improving visual acuity in patients with DME.